An Evaluation of a Pharmacokinetic Interaction Between Tacrolimus and Maraviroc in Allogeneic Stem Cell Transplant Recipients  by Ganetsky, Alex et al.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S286eS296 S289Figures 1 and 2 concur that the minimum PBSC count
required to harvest enough for one or two ASCTs is 10x106/L
and 2x106/L, respectively.
Conclusion: The algorithm has optimized the use of plerix-
afor. The number of doses of plerixafor and ﬁlgrastim, the
days of apheresis and the number of days to ASCT were all
reduced. A successful ﬁrst harvest attempt avoids transplant
delays, reduces the risk of interim disease progression,
avoids scheduling difﬁculties and reduces the stress to the
patient.450
An Evaluation of a Pharmacokinetic Interaction Between
Tacrolimus and Maraviroc in Allogeneic Stem Cell
Transplant Recipients
Alex Ganetsky 1, Todd A. Miano 2, Mitchell E. Hughes 3,
David L. Porter 4, Ran Reshef 4. 1 Hospital of the University of
Pennsylvania, Philadelphia, PA; 2 Center for
Pharmacoepidemiology Research and Training, Perelman
School of Medicine at the University of Pennsylvania,
Philadelphia, PA; 3 Philadelphia College of Pharmacy,
Philadelphia, PA; 4 Blood and Marrow Transplantation
Program, Abramson Cancer Center, Perelman School of
Medicine at the University of Pennsylvania, Philadelphia, PA
Background: Acute graft-versus-host disease (GVHD) re-
mains a leading complication in allogeneic hematopoietic
stem cell transplant (HSCT) recipients. Recently, our group
demonstrated a low rate of visceral acute GVHD with the
addition of maraviroc (MVC), a CCR5 antagonist, to tacroli-
mus (TAC) and methotrexate (MTX) in HSCT recipients(Reshef et al, NEJM 2012). MVC was initiated two days prior
to HSCT and continued until day +30. Limited data are
available regarding whether a pharmacokinetic interaction
exists between TAC and MVC, both CYP3A4 substrates. A
recent case report suggested an increase in TAC exposure
when combined with MVC in a liver transplant recipient
(Dufty et al, J Antimicrob Chemother 2013). We conducted a
retrospective analysis to evaluate whether a pharmacoki-
netic interaction exists between TAC and MVC in HSCT
recipients.
Methods: We retrospectively compared TAC concentrations
and concentration/dose ratios in 36 HSCT recipients
receiving GVHD prophylaxis with TAC/MTX/MVC with a
matched control population of 43 HSCT recipients receiving
TAC/MTX. Ratios were compared at 2 weeks and 6 weeks
following HSCT. Within group comparisons were made using
the Wilcoxon signed-rank test and between-group compar-
isons were analyzed using the Wilcoxon rank-sum test or
Student’s t-test as appropriate. A p-value of  0.05 was
considered signiﬁcant.
Results: The median TAC concentration/dose ratio in the
TAC/MTX/MVC group at week 2 was 2.8 (IQR 1.6 e 4.1) vs.
3.2 (IQR 2 to 4.2) in the TAC/MTX group (p¼0.31). At week 6
(2 weeks after MVC discontinuation), the median TAC
concentration/dose ratio increased in both groups, however
the within group changes were not signiﬁcant (TAC/MTX/
MVC week 2 vs. week 6: 2.8 vs. 3.1, p¼0.071; TAC/MTX
week 2 vs. week: 6 3.2 vs. 4.4, p¼0.077). Concentration/
dose ratios at week 6 were similar between groups: TAC/
MTX/MVC 3.1 (IQR 1.8 to 5.1) vs. TAC/MTX 4.4 (IQR 2.5 to
5.8), p¼0.1. Change from baseline was also similar between
groups: TAC/MTX/MVC 0.2 vs. TAC/MTX 0.5, p¼0.54. The
weekly mean TAC concentrations were similar between
groups at week 1: 11.1 ng/mL vs. 10.7 ng/mL; week 3: 10.1
ng/mL vs. 10.6 ng/mL; and week 4: 10.9 ng/mL vs. 11.8 ng/
mL; (p>0.05 for each week). At week 2, TAC levels were
lower in the TAC/MTX/MVC group (9.5 ng/mL vs. 11 ng/mL;
p¼0.045).
Conclusion: With the exception of week 2, we observed
no signiﬁcant differences in TAC concentrations or con-
centration/dose ratios over time in patients receiving
MVC compared to controls, implying that the protective
effect of maraviroc was not mediated through an increase
in TAC levels. However, the trend towards a decrease in
concentration/dose ratio of TAC upon discontinuation of
MVC suggests an inhibitory effect of MVC on TAC meta-
bolism. Further evaluation of this potential interaction in
larger studies is warranted and close monitoring of TAC
levels is required when the TAC and MVC are co-ad-
ministered.
